Study aim: Comparison of the therapeutic effect of the combination of Erbium YAG laser and stromal vascular fraction (SVF), the combination of Erbium YAG laser and platelet-rich plasma (PRP) and Erbium YAG laser alone in the treatment of striae Design: Clinical trial with control group, with parallel groups, double-blind, randomized with sealed envelopes, phase 2-3 on 10 patients (30 lesions) Settings and conduct: In this study, 10 patients with at least three striae will be treated with Erbium YAG Laser in one session. Then, in the same session, one side is randomly injected with SVF, one side is injected with PRP, and the third side is injected with placebo. Injections are done with syringes of the same shape and color, and the patient, as well as the doctor evaluating the results and the statistician are blinded. Participants/Inclusion and exclusion criteria: Inclusion criteria: The diagnosis of stria distensa based on the diagnosis of a dermatologist, Age less than 50 years and more than 18 years Exclusion criteria: Using any treatment method to remove striae in the last three months, Presence of lesions and skin diseases such as skin cancer or infections, Presence of collagen vascular diseases, Pregnancy and lactation, Using steroids or immunosuppressive drugs Intervention groups: 3 groups: combination of Erbium YAG laser and stromal vascular fraction (SVF), the combination of Erbium YAG laser and platelet-rich plasma (PRP) and Erbium YAG laser alone Main outcome variables: Examining the level of effectiveness based on the Vancouver scale